Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Jack S. Chen(Molecular Oncology (United States)), David Stokoe(Enzo Life Sciences (United States)), Linda J. Zhou(Molecular Oncology (United States)), Mila Donker(Molecular Oncology (United States)), Michal Entin‐Meer(Molecular Oncology (United States)), Xiaodong Yang(Tongji University), William A. Weiss(City College of San Francisco), Kevan M. Shokat(Howard Hughes Medical Institute), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), Zachary A. Knight(Howard Hughes Medical Institute)
Cited by 63
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k